NASDAQ •
Healthcare •
Biotechnology •
Quote as of 09/14/2026 13:18
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization2,897.74 mln
Float66.17 mln
Earnings Date11/11/2026
Piotroski F-Score
1
/ 9
Very weak
Beneish M-Score
74.25
Highly suspicious
1-Year Forecast
58.79
Exceptional upside
Relative Strength
54
/ 100
Slightly ahead
Debt / Equity
0.01
Debt-free
Pre-Tax Margin
-190,221%
Severely loss-making
Business Description
Celldex Therapeutics is a New Jersey-based drug development company focused on creating antibody-based treatments for patients suffering from serious inflammatory, allergic, and autoimmune conditions. Its lead programs target diseases driven by mast cells ? a type of immune cell central to allergic responses ? where existing treatments often fall short. The company's pipeline includes two promising drug candidates being studied across conditions such as chronic hives, a severe skin-scratching disorder, and inflammation of the esophagus and skin.